Dare Bioscience (DARE) Projected to Release Earnings on Thursday

Dare Bioscience (NASDAQ:DARE) is expected to be announcing its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Dare Bioscience to post earnings of ($0.2967) per share and revenue of $0.0020 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Dare Bioscience (NASDAQ:DARE) last announced its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.13. The company had revenue of $0.15 million during the quarter, compared to the consensus estimate of $0.03 million. On average, analysts expect Dare Bioscience to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Dare Bioscience Stock Performance

Shares of DARE opened at $1.34 on Thursday. The firm has a market cap of $20.21 million, a P/E ratio of -1.41 and a beta of 1.08. Dare Bioscience has a twelve month low of $1.13 and a twelve month high of $3.78. The firm’s 50 day moving average price is $1.86 and its two-hundred day moving average price is $1.91.

Analysts Set New Price Targets

A number of equities research analysts recently commented on DARE shares. Weiss Ratings restated a “sell (e+)” rating on shares of Dare Bioscience in a report on Friday, July 17th. Wall Street Zen upgraded Dare Bioscience to a “hold” rating in a report on Saturday, May 23rd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Dare Bioscience has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in DARE. Raymond James Financial Inc. grew its holdings in shares of Dare Bioscience by 810.6% in the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 13,650 shares in the last quarter. LPL Financial LLC bought a new stake in Dare Bioscience during the fourth quarter worth about $28,000. Finally, Virtu Financial LLC bought a new stake in Dare Bioscience during the third quarter worth about $37,000. Institutional investors own 6.70% of the company’s stock.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.